Fierce Biotech August 21, 2024
BridgeBio Pharma is once again spinning out a chunk of its pipeline, this time offloading a handful of early-stage genetic disease programs to a new company called GondolaBio.
The move comes as the California-based biopharma awaits an FDA decision for acoramidis, an investigational heart disease med designed to treat transthyretin amyloid cardiomyopathy. The FDA’s decision is slated for this November. If approved, acoramidis would go up against Pfizer’s tafamidis—sold as Vyndaqel and Vyndamax—and possibly Amvuttra as Alnylam prepares a label expansion request.
Newly formed GondolaBio will conduct R&D, manufacturing and commercialization activities for early-stage clinical or preclinical programs across three indications: a rare inherited metabolic disorder known as erythropoietic protoporphyria, a genetic lung condition called alpha-1 antitrypsin deficiency and a...
Today's Sponsors
Today's Sponsor